| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PCTK2 |
| Uniprot No | Q00537 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-523 aa |
| 活性数据 | MKKFKRRLSLTLRGSQTIDESLSELAEQMTIEENSSKDNEPIVKNGRPPTSHSMHSFLHQYTGSFKKPPLRRPHSVIGGSLGSFMAMPRNGSRLDIVHENLKMGSDGESDQASGTSSDEVQSPTGVCLRNRIHRRISMEDLNKRLSLPADIRIPDGYLEKLQINSPPFDQPMSRRSRRASLSEIGFGKMETYIKLEKLGEGTYATVYKGRSKLTENLVALKEIRLEHEEGAPCTAIREVSLLKDLKHANIVTLHDIVHTDKSLTLVFEYLDKDLKQYMDDCGNIMSMHNVKLFLYQILRGLAYCHRRKVLHRDLKPQNLLINEKGELKLADFGLARAKSVPTKTYSNEVVTLWYRPPDVLLGSSEYSTQIDMWGVGCIFFEMASGRPLFPGSTVEDELHLIFRLLGTPSQETWPGISSNEEFKNYNFPKYKPQPLINHAPRLDSEGIELITKFLQYESKKRVSAEEAMKHVYFRSLGPRIHALPESVSIFSLKEIQLQKDPGFRNSSYPETGHGKNRRQSMLF |
| 分子量 | 86 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人PCTK2蛋白的3篇参考文献示例(注：以下内容为模拟生成，可能与实际文献存在差异，建议通过学术数据库核实)：
---
1. **文献名称**：*Structural insights into PCTK2 kinase and its cyclin binding specificity*
**作者**：Mikolcevic, P., et al.
**摘要**：本研究解析了PCTK2激酶的结构，揭示了其与不同细胞周期蛋白(如Cyclin D3)的结合模式，并证明其磷酸化活性在细胞周期G2/M期调控中的作用，为理解CDK相关激酶家族的功能提供了新视角。
2. **文献名称**：*PCTK2 phosphorylates p53 to promote cell survival under genotoxic stress*
**作者**：Han, X., et al.
**摘要**：该研究发现重组人PCTK2蛋白可直接磷酸化肿瘤抑制蛋白p53的特定位点，抑制其促凋亡功能，提示PCTK2在DNA损伤应答中可能通过调控p53活性促进癌细胞存活。
3. **文献名称**：*Development of a high-throughput screening assay for PCTK2 inhibitors using recombinant protein*
**作者**：Gupta, R., & Lee, S.
**摘要**：研究描述了一种基于重组表达的人源PCTK2蛋白的激酶活性检测方法，用于高通量筛选小分子抑制剂，为靶向PCTK2的抗癌药物开发提供了技术基础。
---
**提示**：若需真实文献，建议在PubMed或Google Scholar中检索“PCTK2”或“CDK15”(PCTK2的别称)，并筛选涉及重组蛋白表达、功能机制或疾病相关的研究。
Recombinant human PCTK2 (PCTAIRE kinase 2) protein is a cell cycle-regulated serine/threonine kinase belonging to the CDK (cyclin-dependent kinase) superfamily. Structurally, it contains a conserved N-terminal PCTAIRE motif and a C-terminal catalytic kinase domain, distinguishing it from classical CDKs. Unlike typical CDKs, PCTK2 activity is independent of cyclin binding but may interact with Cyclin Y or other regulatory proteins. It plays a role in cell cycle progression, particularly during the G1/S transition, and participates in neuronal development, differentiation, and survival through phosphorylation targets involved in cytoskeletal dynamics and vesicular trafficking.
Dysregulation of PCTK2 has been implicated in cancer progression, neurodegenerative disorders, and intellectual disabilities. Overexpression is observed in breast and prostate cancers, correlating with poor prognosis, while mutations are linked to X-linked intellectual disability syndromes. Recombinant PCTK2 is typically produced in bacterial or mammalian expression systems with affinity tags (e.g., His-tag) for purification. Its applications span biochemical studies, kinase activity assays, and drug discovery efforts aiming to develop selective inhibitors. Research tools utilizing recombinant PCTK2 continue to clarify its physiological roles and therapeutic potential in disease models.
×
